Flavin Financial Services Inc. Trims Stock Position in Kenvue Inc. $KVUE

Flavin Financial Services Inc. lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 48,058 shares of the company’s stock after selling 1,229 shares during the quarter. Flavin Financial Services Inc.’s holdings in Kenvue were worth $1,006,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Cambridge Investment Research Advisors Inc. lifted its position in shares of Kenvue by 4.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after purchasing an additional 4,034 shares in the last quarter. Renaissance Capital LLC raised its holdings in Kenvue by 8.3% in the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after acquiring an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Kenvue by 80.7% in the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after acquiring an additional 16,164 shares during the last quarter. Arlington Partners LLC purchased a new position in Kenvue in the second quarter worth approximately $2,110,000. Finally, Cornell Pochily Investment Advisors Inc. lifted its stake in Kenvue by 144.6% in the second quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock worth $694,000 after acquiring an additional 19,609 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of Kenvue stock opened at $15.30 on Friday. The firm’s fifty day simple moving average is $18.54 and its 200-day simple moving average is $21.04. The stock has a market capitalization of $29.37 billion, a price-to-earnings ratio of 20.68, a PEG ratio of 2.20 and a beta of 0.72. Kenvue Inc. has a 12 month low of $14.05 and a 12 month high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 5.4%. Kenvue’s payout ratio is 112.16%.

Analyst Ratings Changes

KVUE has been the subject of a number of recent research reports. Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $22.50 to $22.00 in a research note on Friday, September 26th. Evercore ISI decreased their price target on shares of Kenvue from $23.00 to $18.00 and set an “in-line” rating for the company in a research note on Tuesday, September 23rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Finally, Citigroup decreased their price target on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.